TNF-R.
pendent cytotoxicity and TNF secretion by monocytes has been reported. 29 We describe the effect of GM-CSF administration to patients regenerating from high-dose chemotherapy on expression and secretion of monocyte-associated TNF and TNF-R p55 and p75.
exhibited no other life-threatening cardiac, hepaticknal, or microbiologic disease gave informed consent. All protocols were approved by the Local Ethics Committees. Eight patients receiving high-dose chemotherapy alone without growth factor support were used as parallel patient controls. Additionally, a total of 64 age-and sexmatched control subjects (26 men [median age, 35 .5 years; range, 24 to 59 years] and 38 women [median age, 33.6 years; range, 26 to 60 years]) were studied simultaneously for each patient blood sample taken, such that one control subject was studied for each patient assay.
Preparation of human peripheral blood mononuclear cells (PBMNCs). Blood (50 to 60 mL) in 10 IU/mL of preservativefree heparin was collected before chemotherapy (prebleed [PB] ), at regeneration (R; absolute neutrophil count [ANC], >0.50 X 109/L), and 1 to 3 weeks later (postregeneration [PR] ). Five milliliters of whole blood was taken for flow cytometric assays. The remainder was separated by density centrifugation over Histopaque 1077 (Sigma; d = 1.077 g/mL) for 15 minutes at 600g (18°C). Interface cells were harvested; washed four times in Hanks' Balanced Salt Solution (HBSS) without calcium and magnesium, supplemented with 10 mmoVL HEPES, pH 7.40, and 2.5% fetal bovine serum (FBS; 6 minutes at 450g and 18°C); and resuspended in complete Dulbecco's modified Eagle's medium (DMEM). The resultant PBMNC fraction contained less than 5% platelets using automated differential cytometry and stained positive for the following lineagespecific surface markers: CD14, 16% ? 4%; CD64, 17% ? 4%; CD3,55% -t 6%; CD19,9% 2 3.3%; and CD56,22% 2 8.3%. An aliquot of the PBMNC fraction at a concentration of 2 X IO' cells/ plate was incubated on tissue culture-treated plastic petri dishes that had been primed with 25% voVvol heat-inactivated autologous serum in DMEM for 60 minutes to enrich for the adherent monocyte fraction. Monocytes obtained were routinely 92.5% pure (range, 86.5% to 95.5%) using morphologic and immunophenotypic criteria (<5% CD3, <5% CD56,94.0% t 5.5% CD64, and 89.8% ? 5.2% CD14) and were greater than 95% viable using trypan blue exclusion assay.
Cell culture. The TNF-sensitive cell lines L929 and WEHI-l64 were maintained in DMEM culture medium (Sigma) supplemented with 12.50% voUvol FBS, 2 mmoVL L-glutamine, and streptomycin and penicillin-G antibiotics. primary cells (monocytes and whole PBMNCs) were cultured in DMEM with 5% voVvol FBS, 11 mmoU L glucose, and 2 mmoVL L-glutamine without antibiotics (complete DMEM). Antibiotics were not added because we have found that penicillin and streptomycin at concentrations used in cell culture applications are cytotoxic to freshly isolated primary cells. Cultures were maintained at 37°C in 5% CO2& and 90% relative humidity. Cell lines and primary cells were greater than 95% viable using trypan blue exclusion and were maintained mycoplasma-free for the duration of the assays.
Flow cytometric quantiration of transmembrane expressed TNFa and the TNF-R (TNF-p55 and TNF-p75). Heparinized (10 IU/mL) whole blood was incubated with control diluent (HHBS [ l 0 mmoU L HEPES in Hanks' Balanced Salt Solution] supplemented with 2 mmoVL L-glutamine and 0.50% bovine serum albumin [BSA]) with or without LPS (1 pLg/mL) at 37°C in a shaking water bath for 150 minutes. Fifty microliters of whole blood was then removed and incubated with 50 pg/mL of FITC-conjugated anti-TNF or 25 pg/ mL of anti-TNF-R antibody. Specific epitope recognition by the FITC-conjugated anti-TNF was confirmed by preincubating aliquots of whole blood with unconjugated monoclonal antihuman TNF-neutralizing antibody. This showed that subsequent detection of transmembrane TNF was not observed and that Fc-receptor-mediated nonspecific binding was minimal, thus confirming the TNF-specific recognition by the FITC-conjugated anti-TNF. Samples stained for transmembrane TNF were lysed with FACSlyse solution (Becton Dickinson, Conley, Oxford, UK) diluted 1:lO with sterile deionized water, washed twice in HHBS (supplemented with 2 mmoVL Lglutamine, 0.50% BSA, 10 mmoVL HEPES, pH 7.4, and 0.01% sodium azide solution) at 450g and 4"C, and resuspended in the wash buffer containing 1 % voUvol formaldehyde solution. Samples stained for the p55 and the p75 receptors were washed three times in excess wash buffer at 4°C and incubated on ice for 30 minutes with excess PE-conjugated goat-antimouse F(ab')z fragments. Stained samples were washed three times and finally resuspended in 1% voUvol formaldehyde fixative solution.
A Becton Dickinson FACScan flow cytometer incorporating the Consort 32 LYSYS I1 version 1.02 software was used to assess both the percentage positivity and mean fluorescence intensity (MFI) before and after LPS stimulation. Using this technique, representative levels of percentage positivity for surface TNF in the patient and control groups were 5.3% to 46.6% for resting monocytes and 6.8% to 74.8% for LPS-stimulated monocytes. For the p55 receptor, expression ranged from 6.3% to 17.9% in the resting state and from 6.2% to 29.7% when stimulated. For the p75 receptor, expression ranged from 14.9% to 27.7% in the resting state and from 15.5% to 48.3% while stimulated. MFI for TNF expression ranged from 29.8 to 60.6 in the resting state and from 31.6 to 85.7 when stimulated with LPS. For the p55 receptor, expression MFI ranged from 25.5 to 48.1 in the resting state and from 28.2 to 69.5 when stimulated. For the p75 receptor, expression MFI ranged from 32.8 to 58.3 in the resting state and from 35.4 to 76.5 when stimulated. Spectral compensation was made for red emissions (FL2) entering the green channel ( E l ) and green emissions ( E l ) entering the red channel (FL2) as appropriate (range, 0.50% to 7.0%). Monocyte gates were confirmed by CD14 and CD64 expression for each sample. Data sets were recorded in real time for 1% voVvol formaldehyde solution fixed cell preparations. In single-parameter fluorescence histograms (log,, scale), less than 2% of the monocytes in any one sample stained positive for the appropriate negative isotype control antibody.
Assay of monocyte-mediated TNFa and TNF-R secretion. Monocytes at lo5 cells/mL and PBMNCs at IO6 cells/mL were cultured as quadruplicates for 24 hours in complete DMEM. A similar quadruplicate set was set up and cultured in the presence of LPS at l pg/mL, control cultures were stimulated with control diluent alone. Supernatants were harvested after 24 hours, centrifuged at 400g for 5 minutes at 4"C, passed through a 0.22-pm sterile filter unit, and stored frozen at -70°C until assayed. Secreted proteins were recorded in picograms per lo6 cells.
Assay of bioactive TNF secretion by monocytes and PBMNCs. The bioactivity of secreted TNF was determined by the cytolysis of TNF-sensitive L929 and WEHI-l64 target cells. Target cell monolayers were washed and resuspended to 5 X IO5 cellslmL. One hundred microliters of cells was added to each well of a 96-well flat-based microtiter plate and allowed to equilibrate and adhere for 4 to 6 hours at 37°C before the addition of 100 pL of diluent, standard TNF (10 pg to 1 pg/mL), or supernatant containing actinomycin D (2 PcLg/mL).
After 24 hours, the plates were washed three times with warm divalent cation-free HBSS containing 2 mmoVL L-glutamine and 10 mmoVL HEPES, pH 7.4, and the cells that survived the interaction with TNF were fixed for 2 minutes with 100% methanol, washed twice, and incubated with 100 pL/well of aqueous 1 % voVvol crystal violet solution for 20 minutes. The plate was washed thoroughly with deionized water and 100 &/well 10% voUvol glacial acetic acid was added to solubilize the stained viable cells before being read optically at a wavelength of 620 nm. Data were recorded as the percentage of specific lysis (%SL) with respect to the negative and positive controls and the TNF standard curve. The TNF specificity of this assay was confirmed by preadsorbing culture supernatants with an excess of mouse antihuman TNF neutralizing antibody for For personal use only. on November 11, 2017. by guest www.bloodjournal.org From 2 hours at 37°C. 5% C02/95% air and assaying the supernatants for TNF bioactivity.
Biornerry and sfarisrical analysis. All assays were prepared as duplicates or triplicates for each patient and control. Data are expressed as mean values ? SEM. Independent sample analysis between rhGM-CSF-treated patients and patients treated with chemotherapy alone were compared using the multi-parameter MANOVA (Scheffe Test) and Kruskal-Wallis two-way and three-way ANOVA (fixed effects and repeated measures) for multiple comparisons between and within groups. To test the association between TNF expression and secretion, p55 and p75 expression and secretion, and TNF secretion with TNF-R secretion in the patients and control groups, Peanon's Product Moment Correlation was measured. Significance was set at a-values of P < .05, P < .01, P < , 0 0 1 , and P < .OOOI, as indicated. The Statistica software package (Statsoft UK Ltd. Oxford) was used for data analysis.
RESULTS
Effect of GM-CSF administration on the expression and secretion of TNF. Resting monocytes isolated from normal subjects and patients before chemotherapy exhibited low levels of transmembrane TNF. This effect could be increased by incubation with LPS ex vivo (Figs 1 and 2, P < .01).
Surface TNF levels on monocytes from patients treated with chemotherapy alone were unaltered at and several weeks after hematopoietic regeneration. However, patients treated with GM-CSF exhibited augmented monocyte TNF expression at regeneration and after regeneration compared with before chemotherapy and with patients who had received no growth factor (Figs 2A through F and 3B and C; P < .001). Monocytes from patients that had received chemotherapy alone responded to LPS stimulation with a minimal increase in TNF expression, unlike the response in normal controls (Fig 3) . However, monocytes from patients that had received GM-CSF remained responsive to LPS at both regeneration ( Fig 3B) and several weeks after regeneration (Fig 3C) . TNF expression by monocytes from GM-CSF-treated patients after LPS stimulation was significantly greater than that observed for patients treated with chemotherapy alone at regeneration ( P < .001) and after regeneration ( P < .01).
Secretion of TNF from unstimulated monocytes was low or undetectable but could be augmented after LPS stimulation (Fig 4) . Monocytes from patients receiving chemotherapy alone exhibited a minimal response to LPS at regeneration ( Fig 4B) and after regeneration (Fig 4C) , with the amount of TNF secreted being significantly less than that found before chemotherapy. By contrast, monocytes from patients receiving GM-CSF exhibited increased levels of 
CSF.
Resting (no stimulation) monocyte expression is shown on the left-hand side of the graph and LPS-stimulated monocytes on the right-hand side. LPS stimulation upregulated TNF expression in all patients before chemotherapy. Augmentation of TNF expression was observed in patients treated with rhGM-CSF at regeneration (B) and several weeks after therapy had ceased (C). The data are presented as tho MFI f SEM. *LPS upregulates TNF over resting cells at P < .01. %PS upregulates TNF over resting cells at P < .05. **TNF expression greater than patients treated with chemotherapy alone at P < .01. ++TNF expression greater than that before bleeding at P < .01.
TNF secretion compared with both prechemotherapy levels and with levels in patients who had received no growth factor ( P < .001 for each). In this respect, administration of GM-CSF was able to restore the responsiveness of monocytes to LPS. The TNF secreted was confirmed to be biologically active by cytolysis of WEHI 1 6 4 and L929 cells (Fig 5A  and B) . TNF secretion, as quantified by the bioassay, was in good agreement with that obtained by ELISA.
Secretion of TNF by whole PBMNCs was similar to that of purified monocytes although the levels of TNF secretion per MNC was less than those for monocytes, confirming that monocytes are the main source of secreted TNF from immune effector cells. As for purified monocytes, secretion of TNF was greatly augmented in patients receiving GM-CSF, and the apparent refractoriness to LPS was abrogated (data not shown). However, this effect was observed at regeneration only (data not shown) and did not persist after the growth factor was stopped, as was observed for purified monocytes.
Effect of rhGM-CSF administration on the phenotypic expression of the p55 TNF-R and the p75 TNF-R on monocytes ex vivo. The expression of both p55 (Fig 6) and p75 (Fig  7) was studied in control subjects and patient groups during therapy. In normal control subjects, the resting (unstimulated) monocyte p55 expression was always proportionally lower than the respective expression of p75 ( P < .05). Both the p55 and p75 TNF-Rs were upregulated after LPS stimulation ( P < .01).
-I
No Treatment LPS TNF was minimal in patients and controls before chemotherapy and during regeneration. LPS stimulation induced a significant release of TNF before chemotherapy (A). GM-CSF-treated patients exhibited a marked augmentation in TNF secretion at regeneration (B) that persisted for several weeks after regeneration (C). Patients treated with chemotherapy alone released insignificant levels of TNF at regeneration and several weeks after regeneration. The data are presented as TNF secretion in nanograms per 10'' cells f SEM. *LPS significantly upregulates TNF secretion over resting levels at P < .01. +LPS significantly upregulates TNF secretion over resting levels at P < .05. **The observed secretion of TNF was greater than that of patients treated with chemotherapy alone at P c .W1. ++The observed TNF secretion was greater than the prebleed levels at P c .OOl .
For personal use only. on November 11, 2017. by guest www.bloodjournal.org From At regeneration, monocytes from patients treated with chemotherapy alone exhibited levels of p55 that were similar to those observed before initiation of the chemotherapy ( Fig  6B) ; however, monocytes from patients who had received rhGM-CSF therapy exhibited an increase in p55 expression ( P < .01). Expression levels of p55 returned to baseline after regeneration, which was several weeks after the cessation of rhGM-CSF therapy (Fig 6C) .
WILLIAMS ET AL
Monocytes from patients receiving chemotherapy alone exhibited an augmented expression of p55 over resting levels in response to LPS stimulation, although the response was diminished at regeneration and after regeneration. By contrast, LPS-stimulated monocytes from patients receiving rhGM-CSF exhibited significantly augmented expression levels of p55 at regeneration and after regeneration compared with resting levels ( P < .01). The expression of p55 after LPS stimulation was significantly greater than that observed for patients receiving chemotherapy alone at both regeneration and even after the cessation of rhGM-CSF therapy ( P < ,0001). The levels of p55 in the rhGM-CSF treated patients also remained greater than the prebleed levels at both regeneration and several weeks after the rhGM-CSF therapy had ceased. The phenotypic modulation of p75 in patients receiving only chemotherapy as well as those that received rhGM-CSF therapy followed the same trends as were observed for p55 (Fig 7) .
Effect of rhGM-CSF administration on the secretion of p55 TNF-R and p75 TNF-R from monocytes ex vivo. Resting monocytes secreted low levels of p55 (Fig 8) and p75  (Fig 9) , although both receptors were secreted in response to LPS stimulation. However, before chemotherapy all patients chemotherapy alone responded weakly to LPS at regeneration ( P < .W) and failed to respond to LPS several weeks after regeneration.
Patients treated with rhGM-CSF uchWed marked increases in m mbran8 e x p r d TNF at both regeneration and several weeks after the cessation of therapy in response to LPS. In addition, the levels of p55 expreaaed were aignificanUy greater than those of either normal controls or patients treated with chemotherapy alone. Levels of significance are as described In Fig 2. For
GM-CSF REGULATES MONOCYTE TNF & TNF RECEPTORS
exhibited significantly higher levels of spontaneous p55 secretion compared with normal controls (P < .01). Spontaneous secretion of p75 in both patient groups before chemotherapy was similar to that of normal controls (Figs 8A and 9A) .
At regeneration and after regeneration, resting monocytes from patients treated with chemotherapy alone exhibited lower levels of p55 secretion compared with prebleed levels (Fig 8B and C; P < .05) . By contrast, monocytes from patients who were treated with rhGM-CSF secreted similar levels of TNF-R after regeneration as before chemotherapy, such that levels were marginally greater at time points after regeneration compared with those of patients who had received only chemotherapy (P < .01). Monocytes from patients receiving chemotherapy alone showed reduced ability to respond to LPS at regeneration. However, responsiveness to LPS was restored in patients receiving GM-CSF.
Comparing patients receiving chemotherapy alone and those that had received rhGM-CSF therapy showed striking differences in p75 (Fig 9) . Before chemotherapy, p75 secretion was similar to that observed for normal subjects. However, secreted levels of p75 were markedly attenuated at both ..
I .

No Stimulation LPS
c -1
Assay of monocyte p55 secretion. Spontaneous release of p55 receptors (shown on the left) were low in normal controls. However, the spontaneous release of p55 in both patient groups was greater than that of normals before chemotherapy (A), at regeneration (B) and several weeks later (C). Both patients and controls secreted increased levels of p55 in response to LPS before chemotherapy (shown on the right). At regoneration, patients treated with chemotherapy alone secreted normal levels of p55. Patients treated with rhGM-CSF secreted greater levels of ps5 at regeneration and several weeks after rhGM-CSF therapy had ceesed. The indicated significance levels have been described in Fig 4. regeneration and several weeks after regeneration in patients receiving chemotherapy alone ( P < .01). GM-CSF therapy had a minimal effect on p75 secretion by resting monocytes.
However, the response to LPS in the two patient groups was quite different. At regeneration, monocytes from patients treated with chemotherapy alone were refractory to LPS, an effect that persisted after regeneration. In addition, levels of p75 secreted in response to LPS at both regeneration and several weeks after regeneration were markedly less than the corresponding levels observed before chemotherapy (P < .OOl) and were significantly lower compared with the levels observed for normal patients (P < .01). By contrast, monocytes from patients treated with rhGM-CSF exhibited significantly greater p75 secretion in response to LPS stirnulation at both time points (P < .001). Levels of p75 secreted by rhGM-CSF-treated patients were persistently greater than the levels observed for patients treated with chemother- apy alone at both regeneration (P < .001) and several weeks after regeneration (P < .01).
A strong positive correlation was observed between the expression of TNF and the subsequent secretion of TNF in patients treated with rhGM-CSF (Y = 310, P < .001) that was not seen in those patients receiving chemotherapy alone at regeneration and several weeks after the cessation of rhGM-CSF therapy. A positive correlation between TNF secretion and p75 secretion in patients treated with rhGM-CSF at prebleed, regeneration, and several weeks after the cessation of rhGM-CSF therapy was also found ( r = .663, P < .01). No correlation was seen in patients receiving chemotherapy alone at either regeneration or after regeneration. There was a significant but weaker correlation between p55 secretion and TNF secretion in patients treated with rhGM-CSF therapy that was not observed in those patients receiving chemotherapy alone ( r = 3 9 , P < .02).
DISCUSSION
It has been shown in vitro that GM-CSF can increase the synthesis and expression of TNF by monocyte^'^.^^ and will WILLIAMS ET AL prime monocytes for subsequent secretion of TNF in response to a secondary stimulus. GM-CSF induces rapid upregulation of TNF mRNA in human monocytes.'h.28~30 This affect facilitates increased surface expression and secretion of TNF after stimulation with bacterial LPS.26.'" GM-CSF may also increase TNF expression dire~tly.'~," Both expression and secretion of TNF are important for monocyte antitumor a~t i v i t y~, ' .~~ and secreted TNF may sustain an autocrine feedback loop potentiating the tumoricidal effe~t.~".'".'~~'~ There is some evidence to suggest that the antitumor potential of monocytes is increased by administration of GM-CSF to patient^.'^.'' However, the effect of GM-CSF administration on TNF and TNF-R regulation by monocytes in vivo has not been studied in detail.
We have shown that expression and secretion of biologically active TNF by monocytes in patients regenerating after chemotherapy is enhanced by administration of GM-CSF. Importantly, both expression and secretion of TNF are minimal unless monocytes are exposed to an appropriate secondary stimulus such as LPS. In addition, GM-CSF therapy overcomes the refractory status of monocytes to LPS that is observed after chemotherapy and restores responsiveness to normal or supranormal levels. These observations confirm in vivo that GM-CSF will activate monocytes directly and, more importantly, will prime them to respond to an appropriate secondary stimulus. Thus, administration of GM-CSF is not associated with widespread, inappropriate TNF release, which may be highly toxic in vivo. Increased expression and secretion of TNF may augment both the antitumor and anti-infective potential of circulating monocytes and tissue macrophages after chemotherapy.
We have also observed that GM-CSF administration modulates monocyte TNF-R expression and secretion after chemotherapy. Expression of both p55 and p75 was increased at regeneration in patients receiving GM-CSF. In addition. secretion of p75 was greatly increased by GM-CSF, particularly after secondary stimulation of monocytes by LPS. Soluble TNF-R play a key role in modulating the activity of TNF under conditions of inflammation or during tumor killing.17.1y, 35 The effect of low levels of TNF can be potentiated in solution by binding to soluble p75; by contrast, excess and potentially harmful levels of TNF can be neutralized by this receptor. In this respect, it is our observation that GM-CSF restores the normal responsiveness of monocytes to LPS after chemotherapy that is of potential importance; secretion of TNF receptor p75 must be appropriate for the levels of monocyte-associated and circulating TNF and for the prevailing conditions. We have shown that, in patients receiving GM-CSF, expression and secretion of TNF correlated well with expression and secretion of TNF receptors.
It is unclear why the effect of GM-CSF administration on monocyte function should persist for several weeks after cessation of growth factor administration. The biologic halflife of GM-CSF after subcutaneous administration is 10 to 14 hours.'6 A possible explanation is the persistence of activated circulating monocytes in the blood for several weeks after GM-CSF exposure in the absence of a well-defined inflammatory site for tissue migration. In vitro and in vivo studies have suggested that GM-CSF administration may inhibit neutrophil migratory capa~ity.".'~ For personal use only. on November 11, 2017. by guest www.bloodjournal.org From These observations suggest that administration of GM-CSF to patients after chemotherapy may restore or even increase the antitumor activity of the monocyte-macrophage system. No direct clinical data yet exist to support a direct antitumor role for GM-CSF, although preliminary evidence suggests that its administration may augment the immediate tumoricidal effects of chemotherapy for high-grade non-Hodgkin's lymphoma independently of cytotoxic drug doses.39
